How to Get Dayvigo (Lemborexant) in Kentucky

What Is Dayvigo and Why Doctors Prescribe It in Kentucky

Dayvigo is a dual orexin receptor antagonist (DORA) that blocks OX1R and OX2R signaling to reduce wakefulness drive, helping adults fall asleep and stay asleep. The FDA approved lemborexant on December 20, 2019, based on the SUNRISE-1 and SUNRISE-2 trial programs. It differs mechanistically from benzodiazepines and Z-drugs, which act on GABA-A receptors and carry higher dependency risk.

SUNRISE-1 (N=1,006) was a 30-day, double-blind, randomized trial published in JAMA Network Open that compared lemborexant 5 mg and 10 mg against placebo in adults with insomnia disorder. Lemborexant 10 mg reduced subjective sleep onset latency by 18.0 minutes versus 5.8 minutes for placebo at month one (P<0.001) [1]. Lemborexant 5 mg reduced subjective wake after sleep onset by 41.1 minutes compared with 18.0 minutes for placebo over the same period (P<0.001) [1]. These findings supported the FDA label [2], which recommends starting at 5 mg and titrating to 10 mg if tolerated.

A second key trial, SUNRISE-2 (N=949 to 12 months), published in Sleep Medicine, found that lemborexant maintained efficacy without evidence of rebound insomnia after discontinuation [3]. The 2023 American Academy of Sleep Medicine (AASM) clinical practice guideline for chronic insomnia states: "We suggest the use of lemborexant as a treatment for sleep onset and sleep maintenance insomnia in adults" [4].

For Kentucky patients specifically, Dayvigo fills a gap when first-line behavioral interventions (Cognitive Behavioral Therapy for Insomnia, CBT-I) are unavailable or have not produced sufficient benefit. About 30% of U.S. adults report insomnia symptoms, and a 2020 CDC analysis found Kentucky among the states with the highest prevalence of short sleep duration, with 44.4% of adults sleeping fewer than 7 hours per night [5].

Who Can Prescribe Dayvigo in Kentucky

Any Kentucky-licensed prescriber with DEA Schedule IV authority may write a lemborexant prescription. That group includes MDs, DOs, nurse practitioners (APRNs), and physician assistants (PAs).

Kentucky APRNs operate under a collaborative practice agreement unless they hold independent prescriptive authority through the Kentucky Board of Nursing. As of 2023, full-practice authority for APRNs remains limited in Kentucky, so most NPs prescribing Schedule IV substances work within a written collaborative agreement with a supervising physician [6]. PAs in Kentucky must also practice under a supervising physician arrangement per KRS 311.840.

From a practical standpoint, this means telehealth platforms that staff NPs or PAs for Kentucky patients must have physician oversight structures in place. Patients should verify that a given telehealth service has a Kentucky-licensed supervising physician on file before scheduling a controlled-substance consultation.

Psychiatrists and sleep medicine specialists are the most common specialists writing Dayvigo prescriptions, but primary care physicians, internal medicine doctors, and family medicine practitioners prescribe it regularly. Board certification in sleep medicine is not required to prescribe lemborexant.

How to Get a Dayvigo Prescription in Kentucky: Step by Step

Getting a Dayvigo prescription in Kentucky follows a predictable path regardless of whether you use an in-person clinic or a telehealth service.

Step 1. Document your insomnia history. Gather records showing chronic insomnia lasting at least 3 months, prior treatments tried (OTC sleep aids, melatonin, CBT-I, or other prescription hypnotics), and any relevant comorbidities such as anxiety, depression, or obstructive sleep apnea. Insurance prior authorization almost always requires documented treatment failure with at least one alternative agent [7].

Step 2. Schedule a consultation. In-person sleep clinics, psychiatry practices, and primary care offices across Kentucky accept new patients for insomnia. Average new-patient wait times at Kentucky sleep medicine practices run 3 to 6 weeks. Telehealth platforms can typically schedule an initial insomnia consult within 24 to 72 hours.

Step 3. Complete the clinical evaluation. The prescriber will review sleep history, administer a validated instrument such as the Insomnia Severity Index (ISI) or Pittsburgh Sleep Quality Index (PSQI), and rule out secondary causes. No specific laboratory work is mandated by the Dayvigo FDA label before prescribing [2], though a prescriber may order a TSH or ferritin if restless legs syndrome is suspected, or a sleep study if sleep apnea has not been ruled out.

Step 4. Receive the prescription. Schedule IV controlled substances in Kentucky may be transmitted electronically. Under Kentucky's Electronic Prescribing of Controlled Substances (EPCS) mandate (902 KAR 55:110), prescribers must use EPCS unless an exemption applies [8]. The prescription is sent directly to your pharmacy of choice.

Step 5. Fill at a Kentucky retail or mail-order pharmacy. Major chains (CVS, Walgreens, Kroger Pharmacy, Walmart Pharmacy) and independent pharmacies across Kentucky stock or can order Dayvigo. Expect a 24 to 48 hour fill window at retail locations.

Telehealth Options for Dayvigo in Kentucky

Kentucky law permits telehealth prescribing of Schedule IV controlled substances when a valid prescriber-patient relationship has been established. The Ryan Haight Online Pharmacy Consumer Protection Act requires at least one in-person medical evaluation before prescribing controlled substances via telemedicine in most circumstances, though the DEA's 2023 proposed telemedicine rules would allow audio-visual-only evaluations for certain Schedule IV substances under specific conditions [9].

Several telehealth platforms currently serve Kentucky residents for insomnia management. When evaluating a telehealth provider, confirm the following: the platform employs or contracts with a Kentucky-licensed prescriber; the prescriber holds a valid DEA registration for Kentucky; the platform uses EPCS-compliant technology; and a supervising physician is on file if the clinician is an NP or PA.

A typical telehealth flow for Dayvigo in Kentucky runs as follows. The patient completes an online intake form covering sleep history, current medications, and prior treatments. A clinician reviews the intake and conducts a synchronous video visit (required for Schedule IV substances). The prescription is sent electronically to the patient's chosen Kentucky pharmacy, generally within the same business day as the visit. Total elapsed time from intake to prescription: 24 to 48 hours for most platforms.

One important practical note: telehealth platforms must comply with the Kentucky Board of Medical Licensure's telehealth regulations, which require that the prescriber either hold a Kentucky license or practice under an interstate medical compact arrangement [10].

Labs and Workup Required Before Dayvigo

No blood tests are required by the Dayvigo label before initiating treatment. The FDA label specifies that the drug should be avoided in patients with severe hepatic impairment (Child-Pugh C) and used with caution in moderate hepatic impairment [2].

Prescribers following AASM 2023 guidelines typically complete the following before writing a Dayvigo prescription [4]:

• A validated insomnia questionnaire (ISI score of 15 or above indicates moderate-to-severe insomnia).
• A review of current medications for CYP3A4 interactions, since lemborexant is a CYP3A4 substrate and concurrent strong CYP3A4 inhibitors such as ketoconazole are contraindicated per the label [2].
• A sleep apnea screen using the STOP-BANG questionnaire or similar tool, because untreated moderate-to-severe OSA increases the risk of respiratory depression with sedative-hypnotics [11].
• A brief depression screen (PHQ-2 or PHQ-9), since insomnia and depression frequently co-occur and may influence treatment choice [12].

Liver function testing (ALT, AST, total bilirubin) may be ordered if the patient has a history of hepatic disease, heavy alcohol use, or abnormal prior labs, given the hepatic metabolism of lemborexant [2]. Otherwise, routine bloodwork before starting Dayvigo is at the prescriber's discretion rather than a label requirement.

Insurance, Prior Authorization, and Cost in Kentucky

Kentucky Medicaid does not cover Dayvigo as of 2025. Patients on Medicaid Managed Care Organization (MCO) plans in Kentucky should confirm formulary status with their specific MCO, as coverage determinations vary. Commercial insurance plans in Kentucky often place lemborexant on Tier 3 or Tier 4, requiring prior authorization (PA).

A typical PA submission for Dayvigo under Kentucky commercial plans requires documentation of [7]:

• Diagnosis of chronic insomnia disorder (ICD-10: G47.00).
• Duration of insomnia (generally 3 months or longer).
• Prior trial and failure of at least one formulary-preferred hypnotic, commonly zolpidem, eszopiclone, or trazodone.
• Statement that CBT-I was offered, unavailable, or previously attempted without adequate response.

PA approval timelines in Kentucky range from 24 hours (urgent) to 14 calendar days (standard), per Kentucky Department of Insurance regulations for managed care organizations.

Without insurance coverage, the retail cash price for a 30-day supply of Dayvigo 5 mg runs approximately $390 to $430 at Kentucky pharmacies. The Eisai patient assistance program (Dayvigo Access Program) may reduce out-of-pocket costs to as little as $30 per month for commercially insured patients who meet eligibility criteria. GoodRx coupons for lemborexant bring costs down to roughly $280 to $310 at some Kentucky retail pharmacies, depending on the location and dispensing pharmacy.

503A Compounding Pharmacies in Kentucky and Lemborexant

503A pharmacies in Kentucky are licensed to compound lemborexant for individual patients when a valid prescription is on file and a specific clinical need exists that cannot be met by the commercially available Dayvigo tablets. The term "503A" refers to Section 503A of the Federal Food, Drug, and Cosmetic Act, which governs traditional compounding pharmacies that prepare medications for specific patients based on a prescription [13].

Compounded lemborexant might be appropriate for patients who require a dose strength not available commercially (Dayvigo comes only as 5 mg and 10 mg), who have a documented allergy to an excipient in the branded tablet, or whose prescriber determines that an alternative formulation is medically necessary.

503A pharmacies in Kentucky must hold a current license from the Kentucky Board of Pharmacy, comply with USP 795 standards for nonsterile compounding, and may not compound copies of commercially available products without a patient-specific rationale per FDA guidance [13]. Patients seeking compounded lemborexant should confirm that their pharmacy holds an active Kentucky Board of Pharmacy license and that the prescribing clinician documents the medical necessity in the chart.

Transferring a Dayvigo Prescription to Kentucky

A Dayvigo prescription issued in another state can be transferred to a Kentucky pharmacy under DEA regulations for Schedule IV controlled substances. Federal law (21 CFR 1306.25) allows a Schedule IV prescription to be transferred between pharmacies one time only, though Kentucky regulations may impose additional restrictions [14].

The practical steps are straightforward. Call the Kentucky pharmacy where you want the prescription filled and provide the name and phone number of the original dispensing pharmacy. The Kentucky pharmacist contacts the original pharmacy to verify and transfer the remaining refills. Schedule IV prescriptions in Kentucky may be refilled up to five times within 6 months of the original issue date, consistent with federal DEA rules [14].

Electronic transfer of Schedule IV prescriptions is permitted in Kentucky when both pharmacies use compatible EPCS systems. Paper prescription transfers must be completed verbally pharmacist-to-pharmacist, with a written record maintained by both pharmacies. Transfer of a prescription that has already been partially filled is permitted; the remaining quantity carries over to the new pharmacy.

How Long Until You Receive Dayvigo in Kentucky

The total timeline from first contact with a prescriber to holding your Dayvigo tablets in hand depends on the care pathway.

For telehealth: intake form and video visit same-day or next day, electronic prescription sent to pharmacy within hours of the visit, and retail pharmacy fill in 1 to 2 business days. Total: 2 to 4 business days if no prior authorization is required.

For in-person with an existing prescriber: prescription written at the visit, sent electronically same day, pharmacy fill in 1 to 2 business days. Total: 1 to 3 business days if the drug is in stock.

For in-person with a new specialist (sleep medicine or psychiatry): new patient wait time of 3 to 6 weeks, then 1 to 3 business days from visit to fill.

Prior authorization extends the timeline. Standard PA review by Kentucky commercial insurers takes up to 14 calendar days. Expedited PA review, available when a prescriber certifies that the standard timeline would seriously jeopardize the patient's health, must be completed within 72 hours under Kentucky MCO regulations. If PA is denied, the appeals process adds 30 or more days.

Mail-order pharmacies that service Kentucky (e.g., Express Scripts, CVS Caremark, OptumRx) typically fulfill a 90-day supply of Dayvigo within 5 to 10 business days of receiving a valid prescription and, where required, PA approval.

Dosing and Administration Essentials

The FDA-approved dosing for Dayvigo is straightforward. The recommended starting dose is 5 mg taken orally no more than 30 minutes before going to bed, with at least 7 hours remaining before the planned wake time [2]. If the 5 mg dose is tolerated but not sufficiently effective, the prescriber may increase to 10 mg. The maximum dose is 10 mg per night.

The drug should not be taken with or immediately after a high-fat meal, as food delays time to peak concentration (Tmax) by approximately 2 hours, potentially impairing sleep onset benefit [2]. Patients should avoid alcohol on the same night they take lemborexant, as additive CNS depression may impair next-day driving ability. The FDA label includes a specific warning about impaired driving the morning after use, particularly at the 10 mg dose [2].

Patients with moderate hepatic impairment should not exceed 5 mg. The drug is contraindicated in severe hepatic impairment. No dose adjustment is needed for renal impairment or older adults per the label, though clinicians often start older patients (age 65 and above) at 5 mg given pharmacodynamic sensitivity.

SUNRISE-2 (N=949) demonstrated that lemborexant maintained significant improvements in sleep onset latency and wake after sleep onset over 12 months without evidence of tolerance or rebound insomnia upon discontinuation [3]. The same trial found no next-morning residual sedation at the 5 mg dose on standard psychomotor testing, and only modest effects at 10 mg that resolved within 9 hours of dosing [3].